Skip to main content
Erschienen in: Clinical Pharmacokinetics 7/2019

27.02.2019 | Original Research Article

The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children’s Oncology Group

verfasst von: Ryan J. Beechinor, Patrick A. Thompson, Michael F. Hwang, Ryan C. Vargo, Lisa R. Bomgaars, Jacqueline G. Gerhart, ZoAnn E. Dreyer, Daniel Gonzalez

Erschienen in: Clinical Pharmacokinetics | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Infants with acute lymphoblastic leukemia (ALL) treated with high-dose methotrexate may have reduced methotrexate clearance (CL) due to renal immaturity, which may predispose them to toxicity.

Objective

The aim of this study was to develop a population pharmacokinetic (PK) model of methotrexate in infants with ALL.

Methods

A total of 672 methotrexate plasma concentrations were obtained from 71 infants enrolled in the Children’s Oncology Group (COG) Clinical Trial P9407. Infants received methotrexate 4 g/m2 intravenously for four cycles during weeks 4–12 of intensification. A population PK analysis was performed using NONMEM® version 7.4. The final model was evaluated using a non-parametric bootstrap and a visual predictive check. Simulations were performed to evaluate methotrexate dose and the utility of a bedside algorithm for dose individualization.

Results

Methotrexate was best characterized by a two-compartment model with allometric scaling. Weight was the only covariate included in the final model. The coefficient of variation for interoccasion variability (IOV) on CL was relatively high at 25.4%, compared with the interindividual variability for CL and central volume of distribution (10.7% and 13.2%, respectively). Simulations identified that 21.1% of simulated infants benefitted from bedside dose adjustment, and adjustment of methotrexate doses during infusions can avoid supratherapeutic concentrations.

Conclusion

Infants treated with high-dose methotrexate demonstrated a relatively high degree of IOV in methotrexate CL. The magnitude of IOV in the CL of methotrexate suggests that use of a bedside algorithm may avoid supratherapeutic methotrexate concentrations resulting from high IOV in methotrexate CL.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.PubMedPubMedCentral Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.PubMedPubMedCentral
3.
Zurück zum Zitat Inaba H, Greaves M, Mullighan C. Acute lymphoblastic leukemia. Lancet. 2013;381:1943–55.PubMed Inaba H, Greaves M, Mullighan C. Acute lymphoblastic leukemia. Lancet. 2013;381:1943–55.PubMed
4.
Zurück zum Zitat Pieters R. Infant acute lymphoblastic leukemia: Lessons learned and future directions. Pediatr Malig Hematol. 2009;4(3):167–74. Pieters R. Infant acute lymphoblastic leukemia: Lessons learned and future directions. Pediatr Malig Hematol. 2009;4(3):167–74.
5.
Zurück zum Zitat Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood. 2006;108(2):441–4.PubMedPubMedCentral Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood. 2006;108(2):441–4.PubMedPubMedCentral
6.
Zurück zum Zitat Palle J, Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, et al. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol. 2005;129(2):189–98.PubMed Palle J, Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, et al. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol. 2005;129(2):189–98.PubMed
7.
Zurück zum Zitat Kotecha RS, Gottardo NG, Kees UR, Cole CH. The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer J. 2014;4(4):e200.PubMedPubMedCentral Kotecha RS, Gottardo NG, Kees UR, Cole CH. The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer J. 2014;4(4):e200.PubMedPubMedCentral
8.
Zurück zum Zitat Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4(2):87–101.PubMed Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4(2):87–101.PubMed
9.
Zurück zum Zitat Bleyer WA. The clinical pharmacology of methotrexate new applications of an old drug. Cancer. 1978;41(1):36–51.PubMed Bleyer WA. The clinical pharmacology of methotrexate new applications of an old drug. Cancer. 1978;41(1):36–51.PubMed
10.
Zurück zum Zitat Baram J, Allegra CJ, Fine RL, Chabner BA. Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow. J Clin Invest. 1987;79(3):692–7.PubMedPubMedCentral Baram J, Allegra CJ, Fine RL, Chabner BA. Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow. J Clin Invest. 1987;79(3):692–7.PubMedPubMedCentral
11.
Zurück zum Zitat Goldman D, Matherly LH, Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther. 1985;28(1):77–102.PubMed Goldman D, Matherly LH, Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther. 1985;28(1):77–102.PubMed
12.
Zurück zum Zitat Gökbuget N, Hoelzer D. High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Ann Hematol. 1996;72(4):194–201.PubMed Gökbuget N, Hoelzer D. High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Ann Hematol. 1996;72(4):194–201.PubMed
13.
Zurück zum Zitat Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med. 1986;314(8):471–7.PubMed Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med. 1986;314(8):471–7.PubMed
14.
Zurück zum Zitat Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose Methotrexate. Oncologist. 2016;21(12):1471–82.PubMedPubMedCentral Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose Methotrexate. Oncologist. 2016;21(12):1471–82.PubMedPubMedCentral
15.
Zurück zum Zitat Methotrexate injection [prescribing information]. Lake Forest, IL: Hospira Inc; 2014. Methotrexate injection [prescribing information]. Lake Forest, IL: Hospira Inc; 2014.
16.
Zurück zum Zitat Huffman DH, Wan SH, Azarnoff DL, Hoogstraten B, Hogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther. 1973;14(4):572–9.PubMed Huffman DH, Wan SH, Azarnoff DL, Hoogstraten B, Hogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther. 1973;14(4):572–9.PubMed
17.
Zurück zum Zitat Holford N, Heo Y-AA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941–52. Holford N, Heo Y-AA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941–52.
18.
Zurück zum Zitat Siegel SE, Moran RG. Problems in the chemotherapy of cancer in the neonate. Am J Pediatr Hematol Oncol. 1981;3(3):287–96.PubMed Siegel SE, Moran RG. Problems in the chemotherapy of cancer in the neonate. Am J Pediatr Hematol Oncol. 1981;3(3):287–96.PubMed
19.
Zurück zum Zitat Milsap RL, Jusko WJ. Pharmacokinetics in the infant. Env Heal Perspec. 1994;102(Suppl 11):107–10. Milsap RL, Jusko WJ. Pharmacokinetics in the infant. Env Heal Perspec. 1994;102(Suppl 11):107–10.
20.
Zurück zum Zitat Stewart C, Hampton E. Effect of maturation on drug disposition in pediatric patients. Clin Pharm. 1987;6(7):548–64.PubMed Stewart C, Hampton E. Effect of maturation on drug disposition in pediatric patients. Clin Pharm. 1987;6(7):548–64.PubMed
21.
Zurück zum Zitat McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, et al. Disposition of antineoplastic agents in the very young child. Br J Cancer. 1992;18:S23–9. McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, et al. Disposition of antineoplastic agents in the very young child. Br J Cancer. 1992;18:S23–9.
22.
Zurück zum Zitat Friis-Hansen BJ, Holiday M, Stapleton T, Wallace WM. Total body water in children. Pediatrics. 1951;7(3):321–7.PubMed Friis-Hansen BJ, Holiday M, Stapleton T, Wallace WM. Total body water in children. Pediatrics. 1951;7(3):321–7.PubMed
23.
Zurück zum Zitat Lönnerholm G, Valsecchi MG, De Lorenzo P, Schrappe M, Hovi L, Campbell M, et al. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;52(5):596–601.PubMed Lönnerholm G, Valsecchi MG, De Lorenzo P, Schrappe M, Hovi L, Campbell M, et al. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;52(5):596–601.PubMed
24.
Zurück zum Zitat Donelli MG, Zucchetti M, Robatto A, Perlangeli V, D’Incalci M, Masera G, et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol. 1995;24(3):154–9.PubMed Donelli MG, Zucchetti M, Robatto A, Perlangeli V, D’Incalci M, Masera G, et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol. 1995;24(3):154–9.PubMed
25.
Zurück zum Zitat Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2(4):e38.PubMedPubMedCentral Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2(4):e38.PubMedPubMedCentral
27.
Zurück zum Zitat Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J. 2012;14(1):119–32.PubMedPubMedCentral Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J. 2012;14(1):119–32.PubMedPubMedCentral
28.
Zurück zum Zitat Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007;59(6):847–53.PubMed Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007;59(6):847–53.PubMed
29.
Zurück zum Zitat Fotoohi K, Skärby T, Söderhäll S, Peterson C, Albertioni F. Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays. J Chromatogr B. 2005;817(2):139–44. Fotoohi K, Skärby T, Söderhäll S, Peterson C, Albertioni F. Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays. J Chromatogr B. 2005;817(2):139–44.
30.
Zurück zum Zitat Skärby T, Jönsson P, Hjorth L, Behrentz M, Böjrk O, Forestier E, et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol. 2003;51(4):311–20.PubMed Skärby T, Jönsson P, Hjorth L, Behrentz M, Böjrk O, Forestier E, et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol. 2003;51(4):311–20.PubMed
31.
Zurück zum Zitat Belz S, Frickel C, Wolfrom C, Nau H, Henze G. High-performance liquid chromatographic determination of methotrexate, 7-hydroxymethotrexate, 5-methyltetrahydrofolic acid, and folinic acid in serum and cerebrospinal fluid. J Chromatogr B. 1994;661(1):109–18. Belz S, Frickel C, Wolfrom C, Nau H, Henze G. High-performance liquid chromatographic determination of methotrexate, 7-hydroxymethotrexate, 5-methyltetrahydrofolic acid, and folinic acid in serum and cerebrospinal fluid. J Chromatogr B. 1994;661(1):109–18.
32.
Zurück zum Zitat Sarkar D. Lattice: multivariate data visualization with R. New York: Springer; 2008. Sarkar D. Lattice: multivariate data visualization with R. New York: Springer; 2008.
34.
Zurück zum Zitat Wickham H. Ggplot2: elegant graphics for data analysis. New York: Springer; 2009. Wickham H. Ggplot2: elegant graphics for data analysis. New York: Springer; 2009.
35.
Zurück zum Zitat Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36.PubMed Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36.PubMed
36.
Zurück zum Zitat Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21(6):735–50.PubMed Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21(6):735–50.PubMed
37.
Zurück zum Zitat Kristoffersson AN, Friberg LE, Nyberg J. Inter occasion variability in individual optimal design. J Pharmacokinet Pharmacodyn. 2015;42(6):735–50.PubMedPubMedCentral Kristoffersson AN, Friberg LE, Nyberg J. Inter occasion variability in individual optimal design. J Pharmacokinet Pharmacodyn. 2015;42(6):735–50.PubMedPubMedCentral
38.
Zurück zum Zitat Baverel PG, Savic RM, Karlsson MO. Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2011;38(1):63–82.PubMed Baverel PG, Savic RM, Karlsson MO. Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2011;38(1):63–82.PubMed
39.
Zurück zum Zitat Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241–57.PubMed Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241–57.PubMed
40.
Zurück zum Zitat Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51–64.PubMed Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51–64.PubMed
41.
Zurück zum Zitat Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338(8):499–505.PubMed Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338(8):499–505.PubMed
42.
Zurück zum Zitat Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703.PubMed Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703.PubMed
43.
Zurück zum Zitat Foster JH, Bernhardt MB, Thompson PA, Smith EO, Schafer ES. Using a bedside algorithm to individually dose high-dose methotrexate for patients at risk for toxicity. J Pediatr Hematol Oncol. 2017;39(1):72–6.PubMed Foster JH, Bernhardt MB, Thompson PA, Smith EO, Schafer ES. Using a bedside algorithm to individually dose high-dose methotrexate for patients at risk for toxicity. J Pediatr Hematol Oncol. 2017;39(1):72–6.PubMed
45.
Zurück zum Zitat Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JHM, et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3(2):e00131.PubMedPubMedCentral Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JHM, et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3(2):e00131.PubMedPubMedCentral
46.
Zurück zum Zitat Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, Relling MV. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia. 2000;14(2):221–5.PubMed Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, Relling MV. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia. 2000;14(2):221–5.PubMed
47.
Zurück zum Zitat Paci A, Veal G, Bardin C, Levêque D, Widmer N, Beijnen J, et al. Review of therapeutic drug monitoring of anticancer drugs part 1: cytotoxics. Eur J Cancer. 2014;50(12):2010–9.PubMed Paci A, Veal G, Bardin C, Levêque D, Widmer N, Beijnen J, et al. Review of therapeutic drug monitoring of anticancer drugs part 1: cytotoxics. Eur J Cancer. 2014;50(12):2010–9.PubMed
48.
Zurück zum Zitat Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, García MJ. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006;45(12):1227–38.PubMed Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, García MJ. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006;45(12):1227–38.PubMed
49.
Zurück zum Zitat Lucchesi M, Guidi M, Fonte C, Farina S, Fiorini P, Favre C, et al. Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. Cancer Chemother Pharmacol. 2016;77(4):857–64.PubMed Lucchesi M, Guidi M, Fonte C, Farina S, Fiorini P, Favre C, et al. Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. Cancer Chemother Pharmacol. 2016;77(4):857–64.PubMed
50.
Zurück zum Zitat Piard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, Rietord A, et al. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007;60(4):609–20.PubMed Piard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, Rietord A, et al. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007;60(4):609–20.PubMed
51.
Zurück zum Zitat Buitenkamp TD, Mathôt RAA, de Haas V, Pieters R, Zwaan CM. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica. 2010;95(7):1106–13.PubMedPubMedCentral Buitenkamp TD, Mathôt RAA, de Haas V, Pieters R, Zwaan CM. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica. 2010;95(7):1106–13.PubMedPubMedCentral
52.
Zurück zum Zitat Min Y, Qiang F, Peng L, Zhu Z. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. Biopharm Drug Dispos. 2009;30(8):437–47.PubMed Min Y, Qiang F, Peng L, Zhu Z. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. Biopharm Drug Dispos. 2009;30(8):437–47.PubMed
53.
Zurück zum Zitat Watanabe M, Fukuoka N, Takeuchi T, Yamuguchi K, Motoki T, Tanaka H, et al. Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the bayesian least-squares method. Biol Pharm Bull. 2014;37(6):916–21.PubMed Watanabe M, Fukuoka N, Takeuchi T, Yamuguchi K, Motoki T, Tanaka H, et al. Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the bayesian least-squares method. Biol Pharm Bull. 2014;37(6):916–21.PubMed
54.
Zurück zum Zitat Jönsson P, Skärby T, Heldrup J, Schrøder H, Höglund P. High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based dose calculation. Pediatr Blood Cancer. 2011;57(1):41–6.PubMed Jönsson P, Skärby T, Heldrup J, Schrøder H, Höglund P. High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based dose calculation. Pediatr Blood Cancer. 2011;57(1):41–6.PubMed
55.
Zurück zum Zitat Dombrowsky E, Jayaraman B, Narayan M, Barrett JS. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit. 2011;33(1):99–107.PubMedPubMedCentral Dombrowsky E, Jayaraman B, Narayan M, Barrett JS. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit. 2011;33(1):99–107.PubMedPubMedCentral
56.
Zurück zum Zitat Fukuhara K, Ikawa K, Morikawa N, Kumagai K. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther. 2008;33(6):677–84.PubMed Fukuhara K, Ikawa K, Morikawa N, Kumagai K. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther. 2008;33(6):677–84.PubMed
57.
Zurück zum Zitat Rousseau A, Sabot C, Delepine N, Delepine G, Debord J, Lachâtre G, et al. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet. 2002;41(13):1095–104.PubMed Rousseau A, Sabot C, Delepine N, Delepine G, Debord J, Lachâtre G, et al. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet. 2002;41(13):1095–104.PubMed
58.
Zurück zum Zitat Anderson B, Holford N. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.PubMed Anderson B, Holford N. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.PubMed
59.
Zurück zum Zitat Nader A, Zahran N, Alshammaa A, Altaweel H, Kassem N, Wilby KJ. Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies : utilization of routine clinical monitoring parameters. Eur J Drug Metab Pharmacokinet. 2017;42(2):221–8.PubMed Nader A, Zahran N, Alshammaa A, Altaweel H, Kassem N, Wilby KJ. Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies : utilization of routine clinical monitoring parameters. Eur J Drug Metab Pharmacokinet. 2017;42(2):221–8.PubMed
60.
Zurück zum Zitat Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, et al. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol. 2006;58(5):626–33.PubMed Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, et al. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol. 2006;58(5):626–33.PubMed
61.
Zurück zum Zitat Aquerreta I, Aldaz A, Giráldez J, Sierrasesúmaga L. Pharmacodynamics of high-dose methotrexate in pediatric patients. Ann Pharmacother. 2002;36(9):1344–50.PubMed Aquerreta I, Aldaz A, Giráldez J, Sierrasesúmaga L. Pharmacodynamics of high-dose methotrexate in pediatric patients. Ann Pharmacother. 2002;36(9):1344–50.PubMed
62.
Zurück zum Zitat Odoul F, Le Guellec C, Lamagnère JP, Breilh D, Saux MC, Paintaud G, et al. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fundam Clin Pharmacol. 1999;13(5):595–604.PubMed Odoul F, Le Guellec C, Lamagnère JP, Breilh D, Saux MC, Paintaud G, et al. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fundam Clin Pharmacol. 1999;13(5):595–604.PubMed
63.
Zurück zum Zitat Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panette JC, et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004;100(8):1724–33.PubMed Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panette JC, et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004;100(8):1724–33.PubMed
64.
Zurück zum Zitat Borsi JD, Schuler D, Moe PJ. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison. Cancer Chemother Pharmacol. 1988;22(1):33–5.PubMed Borsi JD, Schuler D, Moe PJ. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison. Cancer Chemother Pharmacol. 1988;22(1):33–5.PubMed
65.
Zurück zum Zitat Martelli N, Mathieu O, Margueritte G, Bozonnat MC, Daurès JP, Bressolle F, et al. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value ? J Clin Pharm Ther. 2011;36(2):237–45.PubMed Martelli N, Mathieu O, Margueritte G, Bozonnat MC, Daurès JP, Bressolle F, et al. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value ? J Clin Pharm Ther. 2011;36(2):237–45.PubMed
66.
Zurück zum Zitat Tiwari P, Thomas MK, Pathania S, Dhawan D, Gupta YK, Vishnubhatla S, et al. Serum creatinine versus plasma methotrexate levels to predict toxicities in children receiving high-dose methotrexate. Pediatr Hematol Oncol. 2015;32(8):576–84.PubMed Tiwari P, Thomas MK, Pathania S, Dhawan D, Gupta YK, Vishnubhatla S, et al. Serum creatinine versus plasma methotrexate levels to predict toxicities in children receiving high-dose methotrexate. Pediatr Hematol Oncol. 2015;32(8):576–84.PubMed
67.
Zurück zum Zitat Reiss SN, Buie LW, Adel N, Goldman DA, Devlin SM, Doucer D. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol. 2016;95(12):2009–15.PubMedPubMedCentral Reiss SN, Buie LW, Adel N, Goldman DA, Devlin SM, Doucer D. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol. 2016;95(12):2009–15.PubMedPubMedCentral
68.
Zurück zum Zitat Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12(8):1667–72.PubMed Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12(8):1667–72.PubMed
69.
Zurück zum Zitat Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80(5):468–76.PubMed Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80(5):468–76.PubMed
70.
Zurück zum Zitat Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014;78(3):565–71.PubMedPubMedCentral Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014;78(3):565–71.PubMedPubMedCentral
Metadaten
Titel
The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children’s Oncology Group
verfasst von
Ryan J. Beechinor
Patrick A. Thompson
Michael F. Hwang
Ryan C. Vargo
Lisa R. Bomgaars
Jacqueline G. Gerhart
ZoAnn E. Dreyer
Daniel Gonzalez
Publikationsdatum
27.02.2019
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 7/2019
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-00734-0

Weitere Artikel der Ausgabe 7/2019

Clinical Pharmacokinetics 7/2019 Zur Ausgabe